Madrigal Pharmaceuticals, Inc.
Price Action
Technical Summary
EMERGING TRENDMadrigal Pharmaceuticals, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 71), indicating performance broadly in line with the market. Earnings growth of 2% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $521.62 | +3.47% | ABOVE |
| 50 SMA | $487.43 | +10.73% | ABOVE |
| 100 SMA | $503.19 | +7.26% | ABOVE |
| 150 SMA | $499.38 | +8.08% | ABOVE |
| 200 SMA | $471.89 | +14.38% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MDGL in an uptrend right now?
MDGL has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is MDGL overbought or oversold?
MDGL's RSI (14) is 45. The stock is in neutral territory, neither overbought nor oversold.
Is MDGL outperforming the market?
MDGL has a Relative Strength (RS) Rating of 71 out of 99. MDGL is performing about average compared to the market.
Where is MDGL in its 52-week range?
MDGL is trading at $539.73, which is 88% of its 52-week high ($615.00) and 78% above its 52-week low ($265.00).
How volatile is MDGL?
MDGL has a Beta of 0.57 and 52-week volatility of 45%. It's less volatile than the S&P 500 - generally more stable.